Statin myopathies: Pathophysiologic and clinical perspectives

Clinical and Investigative Medicine

Volumn 24, Issue 5, 2001, Pages 258-272

  Baker, S K ^a   Tarnopolsky, M A ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRENOLOL; AMITRIPTYLINE; ATORVASTATIN; BUFURALOL; CALCIUM ION; CERIVASTATIN; CHOLESTEROL; CLOZAPINE; CODEINE; CYTOCHROME P450; DESIPRAMINE; DIAZEPAM; DICLOFENAC; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; IBUPROFEN; MEPHENYTOIN; MEVINOLIN; OMEPRAZOLE; PARACETAMOL; PHENACETIN; PHENYTOIN; PRAVASTATIN; PROGUANIL; SIMVASTATIN; THEOPHYLLINE; TOLBUTAMIDE; UNINDEXED DRUG;

ARTERIOSCLEROSIS; CALCIUM TRANSPORT; CELL MEMBRANE; CHOLESTEROL SYNTHESIS; CLINICAL FEATURE; DRUG EFFECT; HUMAN; HYPERCHOLESTEROLEMIA; MYOPATHY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS;

ANTICHOLESTEREMIC AGENTS; DRUG INTERACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCULAR DISEASES;

EID: 0035197395     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (131)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
2. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
3. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
4. Current perspectives on statins
5. An analysis of the role of coenzyme Q in free radical generation and as an antioxidant
6. Effects of lipids and lipoproteins on thrombosis and rheology
7. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial
8. Suppression of recurrent transient ischemic attacks by a statin agent
9. Rhabdomyolysis due to simvastin. Apropos of a case with review of the literature
10. Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation
11. Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations
12. A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy - A case report
13. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits
14. Feedback and hormonal regulation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase: The concept of cholesterol buffering capacity
15. Unnoticed hypothyroidism and myopathy due to lipid-lowering drugs
16. Hypothyroidism presenting as hypercholesterolaemia and simvastatin-induced myositis
17. Antilipemic agents, hypothyroidism, and rhabdomyolysis
18. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine
19. Rhabdomyolysis in heart transplant patients on HMG-CoA reductase inhibitors and cyclosporine
20. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: Two-year efficacy and safety follow-up
21. Lovastatin: An HMG-CoA reductase inhibitor for lowering cholesterol
22. Pravastatin: A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease
23. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences
24. Simvastatin: A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia
25. Fluvastatin: A review of its pharmacology and use in the management of hypercholesterolaemia
26. Mechanisms of lipid-lowering agents
27. Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin
28. Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions
29. Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction
30. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: Effect on human cytochrome P-450 and implications for metabolic drug interactions
31. New insights into the pharmacodynamic and pharmacokinetic properties of statins
32. Direct vascular effects of HMG-CoA reductase inhibitors
33. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction
34. Enhanced sensitivity of ubiquinone-deficient mutants of Saccharomyces cerevisiae to products of autoxidized polyunsaturated fatty acids
35. Biochemical, physiological and medical aspects of ubiquinone function
36. Protein prenylation: Molecular mechanisms and functional consequences
37. Drugs used in the treatment of hyperlipoproteinemias
38. HMG CoA reductase inhibitor-induced myotoxicity: Pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture
39. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro
40. Inhibition of cholesterol biosynthesis by squalene epoxidase inhibitor avoids apoptotic cell death in L6 myoblasts
41. Action of lovastatin, simvastatin, and pravastatin on sterol synthesis and their antiproliferative effect in cultured myoblasts from human striated muscle
42. Pharmacological control of the mevalonate pathway: Effect on arterial smooth muscle cell proliferation
43. Efficacy and safety of simvastatin (alone or in association with cholestyramine). A 1-year study in 66 patients with type II hyperlipoproteinaemia
44. Lovastatin and elevated creatine kinase: Results of rechallenge
45. Lovastatin, nicotinic acid, and rhabdomyolysis
46. Efficacy and long-term adverse effect pattern of lovastatin
47. Experimental lovastatin myopathy
48. Effects of HMG-CoA reductase inhibitors on skeletal muscles of rabbits
49. Lovastatin/gemfibrozil myopathy: A clinical, histochemical, and ultrastructural study
50. Lovastatin-induced acute rhabdomyolysis
51. Rhabdomyolysis associated with lovastatin and erythromycin use
52. Radiocontrast medium-induced declines in renal function: A role for oxygen free radicals
53. Oxidant mechanisms in toxic acute renal failure
54. Reduced activity of antioxidant enzymes underlies contrast media-induced renal injury in volume depletion
55. Cyclosporin A, an immunosuppressive drug, induces programmed cell death in rat C6 glioma cells by a mechanism that involves the AP-1 transcription factor
56. Lipid-lowering drugs and mitochondrial function: Effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio
57. Effects of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolemia
58. Lovastatin decreases coenzyme Q levels in humans
59. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: A double-blind, placebo-controlled study
60. Serum ubiquinone Q10 levels: Effect of cholesterol lowering drugs
61. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer
62. Lovastatin decreases coenzyme Q levels in rats
63. Lipid peroxidation and changes in the ubiquinone content and the respiratory chain enzymes of submitochondrial particles
64. Relations between tocopherol depletion and coenzyme Q during lipid peroxidation in rat liver mitochondria
65. Involvement of tyrosine phosphorylation in HMG-CoA reductase inhibitor-induced cell death in L6 myoblasts
66. HMG-CoA reductase inhibitor-induced L6 myoblast cell death: Involvement of the phosphatidylinositol 3-kinase pathway
67. Coenzyme Q10 can in some circumstances block apoptosis, and this effect is mediated through mitochondria
68. Ubiquinone: Metabolism and functions. Ubiquinone deficiency and its implication in mitochondrial encephalopathies. Treatment with ubiquinone
69. Familial cerebellar ataxia with muscle coenzyme Q10 deficiency
70. Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency
71. Mitochondrial encephalomyopathy with coenzyme Q10 deficiency
72. Myocardial preservation by therapy with coenzyme Q10 during heart surgery
73. Coenzyme Q10 in dilated cardiomyopathy
74. Conditioned nutritional requirements and the pathogenesis and treatment of myocardial failure
75. Marked reduction in CSF lactate and pyruvate levels after CoQ therapy in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS)
76. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors
77. The role of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in the regulation of ubiquinone synthesis in human fibroblasts
78. Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome
79. Lovastatin, isoprenes, and myopathy
80. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin
81. Mitochondrial encephalomyopathy (MELAS): Pathological study and successful therapy with coenzyme Q10 and idebenone
82. Long-term coenzyme Q10 therapy for a mitochondrial encephalomyopathy with cytochrome c oxidase deficiency: A 31P NMR study
83. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) triggered by valproate therapy
84. Effect of coenzyme Q10 in patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): Evaluation by noninvasive tissue oximetry
85. Metabolic changes in patients with mitochondrial myopathies and effects of coenzyme Q10 therapy
86. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle
87. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans
88. Valproate and cytochrome c oxidase deficiency
89. Discharge of newly-synthesized dolichol and ubiquinone with lipoproteins to rat liver perfusate and to the bile
90. Coenzyme Q10, alpha-tocopherol and free cholesterol in HDL and LDL fractions
91. Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors
92. Relation of mevalonate synthesis to mitochondrial ubiquinone content and respiratory function in cultured neuroblastoma cells
93. Effect of simvastatin therapy on blood and tissue ATP levels and erythrocyte membrane lipid composition
94. The participation of coenzyme Q in free radical production and antioxidation
95. Intensification in vivo of free radical oxidation of low density lipoproteins in plasma from patients with myocardial ischemia treated by HMG-CoA-reductase pravastatin and suppression of lipid peroxidation by ubiquinone Q10
96. Increased formation of reactive oxygen species after permanent and reversible middle cerebral artery occlusion in the rat
97. Mitochondrial generation of reactive oxygen species after brain ischemia in the rat
98. Protection by coenzyme Q10 from myocardial reperfusion injury during coronary artery bypass grafting
99. Elucidation of a tripartite mechanism underlying the improvement in cardiac tolerance to ischemia by coenzyme Q10 pretreatment
100. Coenzyme Q10 enhances cardiac functional and metabolic recovery and reduces Ca2+ overload during postischemic reperfusion
101. Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction
102. Clinical experience of coenzyme Q10 to enhance intraoperative myocardial protection in coronary artery revascularization
103. Experimental evaluation of the effects of pravastatin on electrophysiological parameters of rat skeletal muscle
104. Potential risk of myopathy by HMG-CoA reductase inhibitors: A comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers
105. HMG CoA reductase inhibition reduces sarcolemmal Na(+)-K(+) pump density
106. Effects of HMG-CoA reductase inhibitors on excitation-contraction coupling of rat skeletal muscle
107. Role of tyrosine phosphorylation of phospholipase C gamma1 in the signaling pathway of HMG-CoA reductase inhibitor-induced cell death of L6 myoblasts
108. Muscular syndrome after clofibrate
109. Clofibrate-induced acute muscular syndrome
110. Functional reconstitution of the sodium pump. Kinetics of exchange reactions performed by reconstituted Na/K-ATPase
111. Modulation of membrane function by cholesterol
112. Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
113. Phosphatidylinositol 4,5-bisphosphate-induced Ca2+ release from skeletal muscle sarcoplasmic reticulum terminal cisternal membranes. Ca2+ flux and single channel studies
114. The effects of lithium on muscle contractile function in humans
115. Effects of HMG-CoA reductase inhibitors on growth and differentiation of cultured rat skeletal muscle cells
116. Sarcoplasmic reticulum in aged skeletal muscle
117. 2+-ATPase regulation in rat brain: Attenuation with increasing age
118. Aging, energy, and oxidative stress in neurodegenerative diseases
119. Effect of itraconazole on the pharmacokinetics of atorvastatin
120. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations
121. Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin
122. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses
123. HMG-CoA reductase inhibitor-induced myopathy in the rat: Cyclosporine A interaction and mechanism studies
124. Cyclosporin A binding to mitochondrial cyclophilin inhibits the permeability transition pore and protects hearts from ischaemia/reperfusion injury
125. Elucidating the molecular mechanism of the permeability transition pore and its role in reperfusion injury of the heart
126. Rhabdomyolysis after taking atorvastatin with gemfibrozil
127. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors
128. Clinical pharmacokinetics of fibric acid derivatives (fibrates)
129. Cholesterol-lowering agent myopathy (CLAM)
130. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy